Yelena Janjigian: A new treatment for patients with HER2+ gastroesophageal cancer in Europe, US and Brazil

Yelena Janjigian posted on her LinkedIn:

“From preclinical rationale to our Memorial Sloan Kettering Cancer Center Phase II study to today’s ESMO 2023 (European Society for Medical Oncology) presentation of Phase III definitive results that bring a new treatment for patients with HER2+ gastroesophageal cancer in Europe, US, and Brazil. More approvals to come! What an incredible feeling. ”

Source: Yelena Janjigian/Linkedin

Yelena Janjigian is an Associate Professor of Medicine at Weill Cornell Medical College and the Chief of Gastrointestinal Oncology at the Memorial Sloan Kettering Cancer Center in New York. She serves on the Steering Committee of the Giants of Cancer Care and is a member of the International Gastric Cancer Association Council. Dr. Janjigian is a recipient of the ASCO Conquer Cancer Foundation Career Development Award, Debbie’s Dream Foundation Medical Award, and Cycle for Survival Grant Award. She is on the Editorial Board of OncoDaily.